In this Daily Pulse, I walk through why Seatrium’s “material improvement” in H1 net profit is driven mainly by divestment gains and margin tweaks, not yet by proven recurring cashflow. We also cover MAS’ surprise second tightening of monetary policy, plus fresh numbers from iFast and Raffles Medical, to show how a red STI day can still hide quietly positive stories for a Bedok HDB portfolio. The real tension tonight is simple, your CPF and SRS income depends on interest coverage and cash conversion, not on one half-year profit headline. Iggy’s Forensic Zone: Zone 5, Red.
Key takeaways:
Seatrium’s H1 profit uplift is mainly from one-off divestment gains, not recurring cash.
MAS tightened policy again, allowing a stronger Singdollar to contain imported inflation pressure.
iFast’s Q2 net profit rose 35 per cent to around S$29.8 million, with revenue up nearly 38 per cent.
Raffles Medical’s first half net profit slipped 9.6 per cent to S$29 million, with revenue down 6.7 per cent.
A single STI down day masked individual winners and losers, so stock-level news mattered more than the index headline.
Iggy’s Forensic Disclaimer
This content is produced for educational and informational purposes only. I am not a financial advisor — I am a retail investor who applies forensic analysis to my own portfolio and shares that process publicly. Nothing here constitutes a recommendation to buy, sell, or hold any security, and no specific target prices or personalised financial advice are offered. Stocks assessed under Iggy’s Forensic Yield Standard are benchmarked against a 4.7% minimum yield hurdle; stocks flagged as Growth Watch fall below this threshold but demonstrate clean balance sheet metrics and an identifiable growth catalyst — these carry a materially different risk profile and are not suitable as yield replacements for income-dependent investors. All data is sourced from public filings and verified sources; where data is unverified it is explicitly flagged. All investments carry risk, including the potential loss of principal, and past performance is not indicative of future results. If you are making investment decisions involving CPF, SRS, or personal capital, please conduct your own due diligence or consult a MAS-licensed financial adviser before committing funds.
